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Proton pump inhibitors (PPIs) are drugs commonly used for many diseases of the gastrointestinal tract, such as gastroesophageal reflux 
disease, erosive esophagitis, and peptic ulcers of the stomach and duodenum. Used for about 30 years, they are currently the most 
effective drugs that reduce the gastric secretion of hydrochloric acid. However, a dramatic increase in their consumption has been 
recently observed. Very often, they are used not in accordance with the guidelines. The consequences of the long-term use of PPIs 
may be various, with the most common side effects being bone fractures, cardiovascular events, recurrent infections, and vitamin and 
mineral deficiencies. Case report: An 82-year-old and a 58-year-old patients who had been taking omeprazole, a PPI for several years, 
developed vitamin B12 and iron deficiency anemia. Both patients were administered PPI orally for nonspecific dyspeptic symptoms. An 
evaluation of the gastrointestinal tract did not reveal the evident causes of gastrointestinal blood loss. They were also screened negative 
for Helicobacter pylori infection. Conclusions: There are no definitive pieces of evidence that the long-term use of PPIs can induce anemia, 
but our cases strongly suggest this thesis. Physicians should be aware of this potential side effect and consider monitoring in high-risk 
patients.
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Introduction
Proton pump inhibitors (PPIs) are irreplaceable in the treatment 
of many common diseases of the gastrointestinal tract, such as 
gastroesophageal reflux disease (GERD), erosive esophagitis, and 
peptic ulcers of the stomach and duodenum. The main mechanism of 
their action is the inhibition of ATPase K+/H+ (proton pump), which leads 
to a reduction of the number of hydrogen ions released into the stomach 
and results in decreased production of gastric acid, increased pH, and 
hypo- or achlorhydria. In medicine, PPIs have been used for about 
30 years. Recently, a drastic increase in their consumption has been 
observed. Relatively low price, high efficiency, and wide availability 
(over-the-counter (OTC) drugs) lead to their increased usage but not in 
accordance with the applicable guidelines, for example in prophylaxis 
of stress ulcer in patients with low risk of bleeding, either in combination 
with many other pharmaceuticals as “gastroprotective” drugs or with the 
treatment of nonspecific abdominal symptoms. It has been estimated 
that PPIs were prescribed 119 million times in the United States in 2009 
and that patients spend over 24 billion dollars a year globally [1, 2]. 
The number of reports of the danger that might be caused by the 
long-term use of these drugs is still rising [2, 3, 4]. The most common 
side effects include bone fractures, cardiovascular events, recurrent 
infections, as well as vitamin and mineral deficiencies. Small intestinal 
bacterial overgrowth (SIBO) frequency is also probably increased 
by PPIs administration. Presumably, SIBO is closely related to 
dysbiosis [5, 6]. This article seeks to address a possible link between 
prolonged PPIs intake and vitamin B12 and iron deficiency anemia and 
uses two case reports to support this thesis.
Case report
Case 1
An 82-year-old male was admitted to the Hematology Department 
for diagnostics toward mild hemolytic anemia. He reported severe 
weakness, apathy, drowsiness, and recurrent dizziness. So far, 
he had been treated for advanced osteoarthritis of the knee joints. 
For several years, he had been regularly taking nonsteroidal anti-
inflammatory drugs (NSAIDs) in high doses (ibuprofen 400–600 mg/
per day and diclofenac about 200 mg/per day) and PPI (omeprazole 
20 mg/per day), which were supposed to protect the gastrointestinal 
mucosa. Laboratory studies showed that there was a decreased 
hemoglobin (Hgb) level of 12.6 g/dl (a normal range: 13.7–17.5 g/dl), 
macrocytosis – mean corpuscular volume (MCV) – 112 fl (a normal 
range: 79–92 fl), prolonged red cell distribution width – standard 
deviation (RDW-SD) – 60.04 fl, increased reticulocyte percentage 
(3.99%), and increased hemolysis index: low concentration 
haptoglobin (0.14 g/l), elevated total bilirubin (2.2 mg/dl) with 
domination of indirect bilirubin, and high lactate dehydrogenase (LDH) 
– 650 IU/l. There was a significantly lowered vitamin B12 concentration 
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in serum (121.2 pg/ml, a normal range: 191–663 pg/ml). 
The iron level was normal (109.8 µg/dl, a normal range: 59–158 µg/dl). 
An evaluation of the gastrointestinal tract did not reveal the 
presence of Helicobacter pylori antigen or blood in the stool. Anti-
parietal cell antibodies (APCAs) were not detected. The control 
ultrasound scan of the abdomen showed only the presence of 
a gallstone with a size of several millimeters in the gallbladder. 
The Coombs test was performed and no antibodies against red 
blood cells (RBCs) surface antigens were detected. The patient did 
not agree to the endoscopic examinations. The patient received 
treatment with parenteral supplementation of vitamin B12 in 
a starting dose of 1,000 µg intramuscularly once a day for a week, 
then once a week for 1 month, and then once a month. The PPI 
was discontinued and analgesia was modified. Drugs from the 
NSAIDs group were switched to low-dose opioids, buprenorphine in 
transdermal patches. The applied treatment improved the condition 
of the patient, caused the disappearance of clinical symptoms, and 
the stabilization of blood count parameters – Hgb (15.6 g/dl), MCV 
(94.1 fl), and vitamin B12 (530 pg/ml), as well as an appropriate 
control of the pain associated with arthrosis of the knee joints.
Case 2
A 58-year-old male was consulted in Hematologic Outpatient 
Department for mild normocytic anemia (Hgb 11.9 g/dl, MCV 85.4 fl), 
which had been observed for about a year. He had numerous 
chronic diseases such as recurrent atrial fibrillation, paroxysmal left 
bundle branch block (LBBB), arterial hypertension, New York Heart 
Association (NYHA) class II heart failure, cardiomyopathy, and 
type II diabetes (requiring insulin therapy). Moreover, the patient 
suffered from recurrent bacterial pneumonia and triple exudative 
pericarditis during the last 2 years, which resulted in hospitalization 
at the intensive care unit (ICU). The cause of pericarditis was 
unclear but due to the fast progression of the disease and 
continuous anticoagulation therapy, the pericardial puncture was 
abandoned. The treatment based on NSAIDs and colchicine 
resulted in the reduction of the symptoms after a couple of weeks. 
During the first hematologic consultation, the patient complained 
of significant weakness, lack of tolerance of physical activity, 
concentration disorders, and sexual dysfunction. He has been 
taking cardiovascular medicines (propafenone, metoprolol, and 
atorvastatin) regularly for several years as well as antihypertensive 
(amlodipine, torasemide, telmisartan, ramipril, captopril, and 
nitrendipine) and antidiabetic drugs (metformin), anticoagulants 
(dabigatran), and the PPI (pantoprazole) as a “protection” of the 
stomach mucosa. The basic laboratory tests revealed a complex iron 
(22 µg/dl, a normal range: 59–198 µg/dl), ferritin (13 µg/l, a normal 
range: 30–400 µg/l), and vitamin B12 (182 pg/ml, a normal range: 
191–663 pg/ml) deficiency. The gastrointestinal tract endoscopy 
did not reveal any gross abnormalities, and the fecal occult blood 
(FOB) was negative. Furthermore, the iron absorption curve did 
not present any satisfactory increase in the iron concentration. The 
baseline serum iron concentration was 34 μg/dl, after 2 h – 51 µg/dl, 
after 4 h – 61 μg/dl. It was recommended that PPIs should be 
discontinued. The treatment included a cycle of intramuscular 
injections of vitamin B12 and iron oral supplementation. In control 
tests performed after 1 month of the treatment, there was an increase 
in Hgb level to 14.6 g/dl, improvement in laboratory indicators of 
iron metabolism – iron (94 µg/dl), ferritin (27 µg/l), and increase 
in concentration of vitamin B12 (490 pg/ml) in serum. Two months 
after the PPI discontinuation and the initiation of the treatment, Hgb 
level achieved 15.1 g/dl. Above all, the patient reported a significant 
improvement in well-being and resolution of symptoms.
Discussion
The relationship between PPIs and vitamin B12
Low pH in the stomach is necessary at the early stages of vitamin 
B12 absorption. So, suppression of gastric acid secretion by PPIs 
may result in impaired absorption and B12 (cobalamin) deficiency [8]. 
The acidic environment and the presence of pepsin allow the release 
of vitamin B12 from binding to the protein. Then, free molecules 
of cobalamin are binding to the R protein secreted by salivary and 
parietal cells. The B12-R protein complex is then transported to the 
duodenum, where it will be broken down by pancreatic enzymes. In 
the next step, free B12 is bound to the internal factor (IF) produced 
by the parietal cells. Eventually, the IF-B12 complex is absorbed in 
the terminal ileum [7].
Clinical observations on the impact of taking PPI-type drugs on the 
B12 absorption processes may be contradictory [7]. Jensen et al. in 
a study conducted in a group of patients taking PPIs in low doses or 
for a short period of time did not show a reduction in the level of B12 
[7, 9]. Similar conclusions were made by Schenk et al. in the group 
of patients taking long-term PPIs (from 3 to 7 years), and they did 
not show statistically significant differences regarding vitamin B12 
concentrations before and after the treatment [10, 11].
However, in a study conducted at Kaiser Permanente in Northern 
California, which included an impressive group of subjects – 25,696 
patients and 184,199 healthy subjects, there was an increased risk 
of vitamin B12 deficiency (OR = 1.65; 95% CI = 1.58–1.73) among 
patients taking PPIs for 2 years and longer [12]. In another study 
comparing the influence of a short-term (<12 months) and long-
term (± 12 months) use of PPI and H2RA on the risk of vitamin B12 
deficiency, the risk was significantly higher in patients from the second 
Fig. 1. Mechanism of anemia in chronic PPIs usage
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group  (OR = 4.46; 95% CI = 1.49–13.33) [13]. In a retrospective 
analysis, Force et al. showed that patients requiring parenteral vitamin 
B12 supplementation in the treatment of megaloblastic anemia were 
statistically more likely to have an earlier history of taking PPI-type 
medicines for at least 10 months [14].
Maes et al. [15] in their review of the side effects of PPIs, argue that 
many pieces of evidence points to an association between PPIs and 
vitamin B12 deficiency, and contradictory data from other reports may 
be caused by a too small group of patients, a too high threshold for 
vitamin B12 deficiency and a wide variety of accompanying diseases. 
A meta-analysis of many studies has shown that the risk of vitamin 
B12 deficiency associated with the use of gastric acid-suppressive 
therapy is around 80%. The control of vitamin B12 level in patients 
taking PPIs chronically seems to have a strong justification.
The patient presented in the first case had been taking PPIs for many 
years and presented megaloblastic anemia with a lowered level 
of B12 vitamin. Withdrawal of omeprazole resulted in a very quick 
replenishment of B12 reserves during supplementary therapy.
Relationship between PPIs and iron deficiency
Iron in the diet occurs in a free form or bound with heme. Gastric acid 
facilitates the absorption of iron unbound to heme by reducing iron 
to a more soluble form [16]. The clinical experience associated with 
PPIs and secondary iron deficiency varies.
Tempel et al. [17] showed no effect on iron absorption during short-
term PPI therapy. Koop et al. [18] also suggest that the prolonged use 
of omeprazole for at least 3–4 years probably will not result in poor 
absorption of iron and ferritin. Other conclusions were presented 
by Sarzyński et al. [19] who noted a significant decrease in blood 
counts compared to baseline values in the adult group of long-term 
PPIs users (>1 year) [19]. In one recent study, Tran-Duy et al. [20] 
showed that PPI therapy for at least 1 year significantly increases the 
risk of iron deficiency. Researchers using the UK Clinical Practice 
Research Datalink (CPRD) database identified a group of 26,806 
iron-deficient patients diagnosed in 2005–2015 and compared them 
with the same randomly selected control group. The adjusted risk 
ratio of iron deficiency among patients receiving PPIs compared 
to those not taking PPIs was 3.60 (95% CI 3.32–3.91) and 1.51 
(95% CI 1.44–1.58).
In the literature, there are single descriptions of clinical cases of 
patients with iron deficiency anemia in the course of PPI therapy. 
Clinical observations can also be found that discontinuation of PPIs 
was sufficient to improve the erythrocytic parameters [21, 22, 23]. 
In our second presented case, patient taking PPIs regularly for 
many years had a very low iron concentration and initial oral iron 
supplementation had no clinical effect. Similarly, the results of the iron 
absorption curve were unsatisfactory. Only after the discontinuation 
of PPIs, the serum iron and Hgb levels were improved.
Conclusions
On the basis of almost 30 years of experience in PPIs use, it should 
be noted that drugs from this group are one of the most effective 
pharmacological methods for reducing the pH in the stomach, and 
thus have an excellent safety profile. However, the prolonged and 
often completely inappropriate use of PPIs without clinical indications 
is a large clinical problem in recent years, which, as shown by many 
studies and our observations, raises concerns about numerous 
short- and long-term side-effects.
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